Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Heptares Therapeutics
Heptares Therapeutics
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Rentschler Biopharma appoints Patrick Cushing as VP Operations for US subsidiary
The novel position will require Dr Cushing to manager operations at the Miford, MA facility in the US
Making the most of each cell: single-use perfusion in biopharma processing
GEA kytero perfusion disk stack separators are pioneering the time- and cost-efficient harvesting of pharmaceutical proteins from cells and facilitating continuous processing,...
Johnson & Johnson submits regulatory application for Tremfya to the European Medicines Agency
The submission included data from the Phase 3 QUASAR programme in ulcerative colitis and the Phase 3 GALAXI programme in Crohn’s disease, which each achieved their primary...
Amolyt receives FDA fast track designation for hypoparathyroidism drug
The therapeutic has been awarded the fast track designation owing to the Phase III Calypso trial, which showed promising efficacy and safety features
Indian government bans three medicines owing to health risks
Decision follows strong stand on suspending marketing of all drugs prohibited for sale in other countries, including the US, UK, EU and Australia
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Media
Heptares enters drug collaboration with Imperial
Heptares, the wholly-owned subsidiary of Sosei Group Corporation, has entered a new drug research and development collaboration with Imperial College London
Manufacturing
Heptares founder Richard Henderson receives Nobel Prize in Chemistry 2017
Research & Development
Heptares enters research and drug discovery collaboration
Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation, launched a new research collaboration under its ORBIT initiative with Juntendo University in Tokyo, Japan
Research & Development
New programme focused on GPCR target implicated in brain cancer
Heptares Therapeutics announced the launch of a new research collaboration under its ORBIT initiative with New York University School of Medicine
Research & Development
Heptares plans relocation to Cambridge, UK
Heptares is planning to create a state of the art research and development facility on Granta Park to support its growth strategy
Research & Development
John Daly Lecture Award for Heptares’ co-founder
Heptares’ co-founder and Chief Scientific Officer, Fiona Marshall, receives 2017 John Daly Lecture Award in recognition of her outstanding contribution to GPCR drug discovery
Research & Development
New insights to advance drug discovery in pain, cancer and inflammation
Heptares collaboration with AstraZeneca yields novel mechanisms of action highlighted from resolved structures of PAR2 bound to antagonist molecules
Subscribe now